고려대학교 의과대학 및 의과학연구지원센터 구성원이 아닌 경우에는 본인인증을 통하여 글을 작성할 수 있습니다.
- 본인인증 후 글을 작성할 수 있습니다.
내 명의의 휴대전화로 비밀번호를 재설정 할 수 있습니다.
Fluctuations in fasting plasma glucose level elevates the risk of developing diabetes by 1.67 times.
The top 25% with high fasting plasma glucose variability has 1.67 times higher risk of developing diabetes.
Preventive care is essential to maintain? low glycemic variability.
For nondiabetic subjects in general medical examination, those with high fasting glycemic variability has a high risk of developing type 2 diabetes (T2D).
Research teams lead by Prof. Choi Kyung-mook and Prof. Kim Jung-a in the endocrinology department at Korea University Guro Hospital have tracked the incidence of type 2 diabetes of 131,744 nondiabetics for 8.3 years from 2007 who went through medical check-ups more than three times between 2002 and 2007. The results showed that the top 25% of those with high glycemic variability had 1.67 times higher risk of developing T2D than the bottom 25%.
Glycemic variability is the change in blood glucose level independent of the mean. After an average 8.3-year-long tracking of subjects in the current cohort research, 9,303 people were diagnosed with T2D during the same period. Among the top 25% with the highest glycemic variability (Group D), 2,846 people were diagnosed with diabetes while the number was 2,083 among the bottom 25% with the lowest glycemic variability (Group A). The results were adjusted for variables such as age, gender, body mass index, family history of diabetes, hypertension, hyperlipidemia, lifestyle factors, and mean fasting plasma glucose.
Prof. Choi Kyung Mook said "Glycemic variability of T2D patients emerged as an important research topic in studies related to diabetic complications and cardiovascular diseases" and "The present study is valuable as the first report showing that fasting glycemic variability of nondiabetics is associated with the risk of developing T2D."
He stressed that prevention of type 2 diabetes requires attention to highly fluctuating blood glucose levels and regular dietary and exercising habits.
The paper was published in the December 2018 issue of Diabetes Care.
pubmed link: https://www.ncbi.nlm.nih.gov/pubmed/30254081
Diabetes Care. 2018 Dec;41(12):2610-2616. doi: 10.2337/dc18-0802. Epub 2018 Sep 25.
Korea University Medical Center makes big strides in becoming a leader in future medicine,
Announcing its mission and vision to lead the future of medicine,
Unveiling a blueprint for futuristic hospitals and selecting 10 leading technologies to advance the future of medicine.
Ensuring the health and happiness of humankind with cutting-edge medical technologies and respect for life
Enabling Future Medicine
Korea University Medical Center (KUMC) is making great strides towards becoming a global leader in biomedicine to better the future of medicine.
Celebrating the 90th anniversary of the College of Medicine in 2018, KUMC declared its ambition and vision to lead the future of medicine in a ceremony held in Inchon Memorial Hall at 5 p.m. on December 12th 2018.
The ceremony was proceeded in the order of a pledge of allegiance to the nation, introduction of guests, congratulatory remarks, vision declaration, video play of leading technologies in future medicine and a toast during a banquet. About 700 guests joined the ceremony including Kim Jae-ho, Chairman of the Board of Directors of the Korea University Foundation, Yeom Jaeho, President of Korea University, Lee Ki-hyung, Vice President of Medical Affairs, Na Chun-gyun, President of the Alumni Association of the College of Medicine as well as Im Young-jin, President of the Korean Hospital Association, Park Gu-seon, Chairman of the Board of Directors of KBioHealth in Osong and Park Hong-jun, President of the Seoul Medical Association.
In the ceremony, KUMC unveiled its mission 'Ensuring the health and happiness of humankind with cutting-edge medical technologies and respect for life.' KUMC was founded in 1928 as the first medical institution for women in Korea who could not see a doctor as they were barred from showing their body to men during the Japanese colonial era. The history of commitments to answer the needs of the era enabled establishment of affiliated hospitals to deliver medical services in Guro and Banwol Industrial Complexes. KUMC announced its goal of writing a new history of medical innovation and contribution to human health through convergent biomedical research in the era of the 4th Industrial Revolution.
KUMC is the sole exemplar in Korea for having two research-oriented hospitals, leading convergent biomedical research by establishing affiliates of a medical holding company for the first time in the history of the Korean medical sector. With advanced research capabilities and concrete aims to realize its mission, KUMC also unveiled the vision of 'Enabling Future Medicine.'
Furthermore, KUMC presented four key strategies in order to make its vision become a reality. KUMC will nurture promising talented individuals into leaders in the 4th Industrial Revolution through 'education for convergent and creative thinking' by collaborating with specialists in diverse areas. As a 'global leader in the biomedical industry', KUMC will also propel next-generation growth momentum into biomedicine with commitments to promote prosperity of the nation. KUMC will lead precision medicine, a major prospect in global medicine, and provide advanced and unique healthcare services for the public through 'customized special treatments' and deliver universal medical services to marginalized and vulnerable people as a medical institution 'realizing people-centered social values.'
KUMC also presented a blueprint for a futuristic hospital. This advanced ‘smart intelligent hospital’ proposed by KUMC connects and utilizes the 4h Industrial Revolution technologies such as IoT, AI, MR and Big Data. KUMC will make all affiliated hospitals a standard for futuristic hospitals including the Anam AI-driven Hospital that started to be built last year with a total construction costs of 350 billion won. Participants of the ceremony gave a rapturous applause after the video demonstration of KUMC's future.
The selection of 10 leading technologies in the next-generation biomedicine drew huge attention from the audience. These ten leading technologies include Cancer Precision Medicine, Cloud-Hospital Information System, AI-based Drug Design, Liquid Biopsy, Human Microbiome, Genome Editing, Patient-on-a-chip, 3D Organ Printing, Wearable Soft Robot and Memory Editing. These technologies will enable KUMC to realize the future of medicine that has thus far been only in the imagination and sci-fi movies.
Why do mitochondria continue a fission-fusion cycle?
Acting as the so-called 'powerhouses of cells,' mitochondria develop mitochondrial membrane potential through their unique metabolism in electron transport chain to produce ATP, the cellular energy source. Though mitochondria generate energy in high efficiency, cells consume huge amount of energy to keep mitochondria healthy because dysfunctional mitochondria could do much harm to cells. Mitochondria continue to change shapes via fission and fusion, which is considered an essential process to keep them functional. For example, damaged mitochondria can recover their function by fusing with healthy ones. Moreover, damaged regions of mitochondria are separated by mitochondrial fission for disposal. Damaged mitochondria usually have low membrane potential and are selectively eliminated through autophagy. Though defects in autophagy are deeply correlated with degenerative brain diseases, diabetes and heart diseases and have been studied by many experts, it is not well understood how a cell can recognize and get rid of damaged mitochondria.
The research team in the lab of anatomy led by Prof. Sun Woong found that Drp1, a protein involved in mitochondrial fission, interacts with mitochondrial zinc transporter Zip1, reduces the mitochondrial membrane potential and cuts mitochondria into pieces to selectively remove those pieces that are not able to restore the membrane potential. As inhibition of Drp1 and Zip1 interaction reduces the mitochondrial membrane potential and blocks the removal of damaged mitochondria, energy synthesizing capabilities of mitochondria are reduced and growth of neurons are interrupted, according to researchers. Based on their results, Prof. Sun Woong's research team set up a hypothesis that cells examine the mitochondrial health through an energy consuming fission process. As the mitochondrial quality control process is very crucial to human health, studies on this topic will be able to provide essential clues to the treatment of diseases caused by dysfunctional mitochondria.
pubmed link: https://www.ncbi.nlm.nih.gov/pubmed/30581142
Mol Cell. 2019 Jan 17;73(2):364-376.e8. doi: 10.1016/j.molcel.2018.11.009. Epub 2018 Dec 20.
Investigation of Mitochondrial Reprogramming via ATP5H Loss in Multimodal Cancer Therapy Resistance
(mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance.)
Cancer immunotherapy has drawn great attention from the medical industry, but it is not readily available, because, generally, the therapeutic outcome is poor, owing to inherent resistance of cancer cells to the treatment. Meanwhile, it has been known that the immune system plays a pivotal role in the emergence of tumor cells that are refractory to multiple clinical interventions, including immunotherapy, chemotherapy, and radiotherapy. But the mechanism is not clear.
A research team led by Professor Tae-woo Kim of Department of Biomedical Sciences suggested new molecular mechanisms by which the immune system triggers cross-resistance to multimodal anti-cancer treatments. In this connection, the researchers witnessed a decline in epigenetic manifestation of ATP5H from tumor cells resistant to immunotherapy, which uses cytotoxic T cells. The team also uncovered that ATP5H loss is involved in the multimodality resistance to therapy, including immune resistance. A loss of ATP5H, one of the components of mitochondrial ATP synthase, triggers cancer metabolic reprogramming along with mitochondrial dysfunction, and promotes multimodality resistance to cancer therapy by accumulating ROS, and leading to ROS-mediated HIF-1α stabilization in normal oxygen conditions. It was proven that in vivo delivery of antioxidants reverses immune-resistant tumors, and phenotypic resistance to anticancer drugs of resistant tumor, and, in doing so, reactivity to the conventional therapies can increases. It was also found that ATP5H loss in tumors was closely linked to the failure of therapy, cancer progression, and poor survival in patients.
The study results clarified the importance of mitochondrial reprogramming via ATP5H loss in the issue of multimodal cancer therapy resistance led by immune system. Further, the research team suggested that targeting the mitochondrial metabolic reprogramming in the tumor cells can be an effective cancer therapy, in an effort to treat refractory cancers resistant to cancer therapy.
The research results were published in Journal of Clinical Investigation under the title, Mitochondrial Reprogramming via ATP5H Loss Promotes Multimodal Cancer Therapy Resistance.
pubmed link: https://www.ncbi.nlm.nih.gov/pubmed/30124467
J Clin Invest. 2018 Aug 31;128(9):4098-4114. doi: 10.1172/JCI96804. Epub 2018 Aug 20.